Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SRZN vs ENSC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SRZN Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

SRZN Overall Winner 6-Pillar Tally: SRZN 4 – 1 ENSC (1 Tie) Matrix Metrics: SRZN 6 – 4 ENSC

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin).

  • Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -281.3% operating margin) and revenue trajectory (+408.6% vs. -15.1% YoY).
  • Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SRZN vs ENSC
SRZN NASDAQ Head-to-Head Winner
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.29β · 73% Vol
Unified Composite Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.2 · SMA20: $30.47 · SMA50: $26.93
ENSC NASDAQ
Ensysce Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$0.36
-0.17% 1D
Market Cap $7.0M
TTM Revenue $4.5M
Forward P/E 0.8x
Beta / 30D Vol 0.98β · 79% Vol
Unified Composite Score
53.4 / 100 HOLD
Tech 50.0 Fund 62.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 40
RSI-14: 39.7 · SMA20: $0.39 · SMA50: $0.44

6-Pillar Scorecard Institutional Category Breakdown (SRZN 4 – 1 ENSC)

Columns: Metric · SRZN · ENSC
1. Valuation Multiples ENSC
Forward P/E N/M 0.8x
Trailing P/E N/M 0.8x
PEG Ratio N/M N/M
EV / Revenue 52.1x 1.4x
2. Growth & Scale SRZN
Revenue Growth (YoY) +408.6% -15.1%
Earnings Growth (YoY) -37.0% +0.0%
TTM Revenue (USD) $11M $4.5M
Market Cap $642.7M $7.0M
3. Profitability & Quality SRZN
Gross Margin N/A N/A
Operating Margin -485.4% -281.3%
Net Profit Margin 0.0% -280.5%
Return on Equity (ROE) -62.8% -1295.1%
4. Balance Sheet & Cash Flow SRZN
Cash Generation (TTM) -$31M -$9.7M
Cash Flow Margin N/A N/A
Net Cash / Leverage $95M Net Cash -$499,633 Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SRZN
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 72.0% (13th %ile) N/A (N/A)
Put/Call OI Skew 21.00x (Put-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SRZN (6) vs ENSC (4)
Institutional Metric SRZN ENSC Criterion Row Edge
Market Capitalization
Scale
$642.7M $7.0M Larger Scale SRZN
Trailing P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Forward P/E Ratio
Valuation
N/M 0.8x Lower Multiple ENSC
Revenue Growth (YoY)
Growth
+408.6% -15.1% Higher Growth SRZN
Operating Margin (TTM)
Profitability
-485.4% -281.3% Higher Margin ENSC
Net Profit Margin
Profitability
0.0% -280.5% Higher Margin SRZN
Return on Equity (ROE)
Capital Efficiency
-62.8% -1295.1% Higher ROE SRZN
52-Week Range Position
Momentum
63% ($13–$38) 8% ($0–$2) Stronger Trend SRZN
Beta / 30D Volatility
Risk Regime
1.29β · 73% Vol 0.98β · 79% Vol Lower Realized Risk SRZN
Unified Institutional Score
Composite Signal
36.0 / 100 (SELL) 53.4 / 100 (HOLD) Higher Composite ENSC
Trailing 12M Revenue (USD)
Operating Scale
$11M $4.5M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 52.1x EV/Rev N/M PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$31M ($95M Net Cash) -$9.7M (-$499,633 Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SRZN +40.07 pp
SRZN: +10.52% · ENSC: -29.55%
3M Horizon SRZN +19.01 pp
SRZN: +18.73% · ENSC: -0.28%
6M Horizon ENSC +5.06 pp
SRZN: +7.93% · ENSC: +12.99%
1Y Horizon SRZN +191.14 pp
SRZN: +110.81% · ENSC: -80.33%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period SRZN Revenue ENSC Revenue SRZN Op. Margin ENSC Op. Margin Margin Leader
FY2020 N/A $0M N/A -41.0% ENSC
FY2021 N/A $0M N/A -562.7% ENSC
FY2022 $10M $0M -354.7% -959.9% SRZN
FY2023 N/A $0M N/A -480.5% ENSC
FY2024 $10M $10M -239.7% -129.2% ENSC
FY2025 $0M $10M -1210.6% -202.1% ENSC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SRZN CONSOLIDATION
41d in phase · OBV NEUTRAL
Current IV 72.0%
IV Percentile 13th %ile
Put/Call OI Skew 21.00x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SRZN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENSC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENSC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SRZN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $642.7M market capitalization and -485.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ENSC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.0M market capitalization and -281.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SRZN vs ENSC Key Questions & Quantitative Answers

As of Nov 20, 2026, Surrozen, Inc. Common (SRZN) is the stronger overall head-to-head candidate over Ensysce Biosciences, Inc. (ENSC) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). SRZN carries a Unified Composite Score of 36.0/100 (SELL) at $28.46 (N/M Forward P/E, -485.4% operating margin), whereas ENSC carries 53.4/100 (HOLD) at $0.36 (0.8x Forward P/E, -281.3% operating margin). Composite vs. Pillar Nuance: While ENSC currently prints a higher short-term Unified Composite Score (53.4/100 HOLD vs. SRZN 36.0/100 SELL), SRZN captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-485.4% vs. -281.3% operating margin) and revenue trajectory (+408.6% vs. -15.1% YoY). Technical & Structure Timing Caution: SRZN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 47.2); meanwhile ENSC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SRZN leads the Growth & Scale pillar: SRZN posts +408.6% YoY revenue growth and -37.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -485.4% operating margin), compared with ENSC at -15.1% YoY revenue growth and +0.0% YoY earnings growth on $4.5M TTM revenue (N/A gross margin, -281.3% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), SRZN cumulative revenue shifted +0.0% while ENSC shifted +0.0%. In operating R&D and SG&A reinvestment, SRZN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ENSC.

ENSC screens cheaper on headline valuation multiples. SRZN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 52.1x EV/Revenue (unreported FCF margin), whereas ENSC trades at 0.8x Forward P/E, 0.8x Trailing P/E, N/M PEG, and 1.4x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRZN (-62.8% ROE) versus ENSC (-1295.1% ROE) capital efficiency.

In options market volatility and institutional positioning, SRZN carries 72.0% implied volatility (13th %ile, Compressed (<25th %ile)), a 21.00x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.29β · 73% Vol realized risk). By comparison, ENSC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.98β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.